Adamas Announces New Employment Inducement Grant
September 17 2019 - 4:15PM
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that
the compensation committee of the company’s board of directors
granted its new Chief Executive Officer, Neil F. McFarlane, the
option to purchase an aggregate of 250,000 shares of the company’s
common stock, at a per share exercise price of $6.25, the closing
trading price on September 16, 2019, and restricted stock units to
acquire 125,000 shares of the company’s common stock. The stock
options and restricted stock units vest over four years and were
granted pursuant to the Adamas Pharmaceuticals, Inc. 2016
Inducement Plan, which was approved by the company's board of
directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global
Market for equity grants to induce new employees to enter into
employment with the company.
About Adamas Pharmaceuticals, Inc.
Adamas’ goal is to create and commercialize a
new generation of medicines intended to lessen the burden of
chronic neurologic diseases on patients, caregivers and society
using its deep understanding of time-dependent biology. The Company
is focused on the commercialization of GOCOVRI® (amantadine)
extended release capsules, the first and only FDA-approved medicine
for the treatment of dyskinesia in patients with Parkinson’s
disease receiving levodopa-based therapy, with or without
concomitant dopaminergic medications. The Company also continues to
deliver differentiated investigational programs, including ADS-5102
in development for the treatment of walking impairment in patients
with multiple sclerosis. For more information about Adamas and its
unique approach to developing medicines based on time-dependent
biology, please visit www.adamaspharma.com.
Contact:
Investors:Peter VozzoWestwicke Partners
443-213-0505peter.vozzo@westwicke.com
Media: Sarah MathiesonVice President, Communications &
Engagement 510-450-3528smathieson@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From May 2024 to Jun 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jun 2023 to Jun 2024